Fate Therapeutics (FATE) Share-based Compensation (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Share-based Compensation data on file, last reported at $3.9 million in Q1 2026.

• Quarterly Share-based Compensation fell 46.77% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 43.34% YoY) and the FY2025 annual result came in at $24.9 million, down 39.94% from the prior year.
• Share-based Compensation slipped to $3.9 million in Q1 2026, from $5.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $78.1 million in Q4 2022 to a low of $558000.0 in Q1 2024.
• A 5-year average of $14.2 million and a median of $9.6 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation slumped 94.92% — and 2025, when it soared 1222.76%.
• Tracing FATE's Share-based Compensation over 5 years: stood at $78.1 million in 2022, then plunged by 87.86% to $9.5 million in 2023, then declined by 3.75% to $9.1 million in 2024, then tumbled by 39.39% to $5.5 million in 2025, then retreated by 28.93% to $3.9 million in 2026.
• The last three Share-based Compensation figures came in at $3.9 million (Q1 2026), $5.5 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.